Survival Benefit Observed With Adjuvant Cemiplimab in Skin Cancer Subtype
Results presented at 2023 ESMO showed a prolonged survival benefit in patients receiving adjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma.
Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma
BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.
Acalabrutinib Combo Shows Promising Outcomes in Mantle Cell Lymphoma
Overall survival rates at 12 and 36 months appear to favor the addition of acalabrutinib to bendamustine and rituximab in the treatment of those with mantle cell lymphoma in a phase 1b trial.
Datopotamab Deruxtecan Combo Shows Responses in Advanced NSCLC
Datopotamab deruxtecan plus pembrolizumab produces no new safety signals in the treatment of patients with advanced non–small cell lung cancer in the phase 1b TROPION-Lung02 trial.
Talazoparib/Enzalutamide Improves Survival Vs Placebo in HRR mCRPC
Talazoparib plus enzalutamide appears to improve the objective response rate vs enzalutamide plus placebo among patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair mutations in the phase 3 TALAPRO-2 study.
RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in Endometrial Cancer
Dostarlimab plus chemotherapy appears to improve progression-free survival vs placebo plus chemotherapy in patients with recurrent endometrial cancer in the phase 3 RUBY trial.
Niraparib Yields Limited OS in Final Analysis for Ovarian Cancer
Niraparib maintenance therapy for recurrent ovarian cancer does not yield a significant overall survival benefit in an updated analysis of the phase 3 ENGOT-OV16/NOVA study.
Lenvatinib Combo Yields Promising Early Activity in Liver Cancer Subtype
Lenvatinib in combination with blank-microsphere transarterial chemembolization and sequential microwave ablation demonstrates encouraging preliminary activity in patients with hepatocellular carcinoma.
Belantamab Mafodotin Monotherapy Produces Durable Response in DREAMM-2 Final Analysis in R/R Multiple Myeloma
The final analysis from the phase 2 DREAMM-2 study found continued efficacy in patients who had relapsed/refractory multiple myeloma.
Neoadjuvant Vs Adjuvant Pembrolizumab Yields Promising EFS Benefit in High-Risk Resectable Melanoma
Patients with high-risk resectable melanoma experienced the highest event-free survival benefit when pembrolizumab was administered in the neoadjuvant settings vs the adjuvant setting
Frontline Tislelizumab Vs Sorafenib Yields Survival Benefit in Unresectable HCC
Results from the phase 3 RATIONALE-301 trial showed improved overall survival for patients who were given frontline tislelizumab for unresectable hepatocellular carcinoma.
Favorable OS Outcomes Observed With Front-Line Durvalumab Plus Tremelimumab in Metastatic NSCLC
Durvalumab plus tremelimumab in the first-line setting yielded improved overall survival vs chemotherapy in patients with metastatic non–small cell lung cancer.
Larotrectinib Trial Yields Promising Real-World Findings in TRK Fusion–Positive Disease
Patients with TRK fusion–positive disease experienced promising survival outcomes following treatment with larotrectinib vs standard of care.
Frontline Sugemalimab Plus Chemo Combo Illicits Greater Survival Vs Chemo Alone in NSCLC
Without regard for tumor pathology or PD-L1 expression, administering sugemalimab in combination with chemotherapy was superior to chemotherapy alone in treating patients with non–small cell lung cancer.
Liso-Cel Leads to Durable Responses in Second-Line Therapy in Relapsed/Refractory LBCL
The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.
Neoadjuvant Durvalumab Plus Tremelimumab Combo Elicits Response in Advanced Ovarian Cancer
Data from the phase 2 KGOG 3046 trial revealed evidence of antitumor activity with the neoadjuvant chemoimmunotherapy regimen containing durvalumab and tremelimumab for patients with advanced-stage ovarian cancer.
AZD5305 Yields Promising Clinical and Safety Findings Across Several Solid Malignancies
Patients with solid malignancies may benefit from treatment with next-generation PARP inhibitor AZD5305, according to findings from the phase 1/2a PETRA study.
Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHN
Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.
East Asian Patients With Advanced RCC Benefit from Lenvatinib Plus Pembrolizumab
Subgroups analysis from the CLEAR trial of lenvatinib plus pembrolizumab showed efficacy results were consistent between East Asian patients and the overall study population.
Olaparib Plus Pembrolizumab Treatment Safe in Advanced Chloangiocarcinoma
Interim results of a phase 2 trial found a safe toxicity profile for olaparib plus pembrolizumab in advanced cholangiocarcinoma.
Safety, Efficacy of Cilta-Cel in Pretreated Myeloma Maintained in Subgroups Analyses
Most subgroups of patients with relapsed or refractory, heavily pretreated multiple myeloma showed durable responses at the 2-year follow-up to the CARTITUDE-1 trial.
Loncastuximab Tesirine Plus Ibrutinib in Relapsed DLBCL Trends Favorably at LOTIS-3 Interim Analysis
Anti-tumor activity coupled with a manageable safety profile was noted with the combination of ibrutinib plus loncastuximab tesirine for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma at an interim analysis of the LOTIS-3 trial presented at 2021 ASH.
Black Women Experience More Treatment Modifications Than White Women With Breast Cancer
Black patients may have poorer outcomes during breast cancer treatment than White patients.
Examining Social Inequity and Racial Disparities in T-Cell Lymphoma
As treatment for T-cell non-Hodgkin lymphomas continues to expand, disparities and inequities continue to grow for those within certain racial groups and of a certain socioeconomic status.
Nivolumab Plus Ipilimumab Yields Durable Survival Benefit in Advanced RCC
Patient with advanced renal cell carcinoma who were treated with nivolumab and ipilimumab experienced a long-term survival benefit that was superior to sunitinib.
Promising Preliminary Data for KRAS G12C Inhibition With Adagrasib Are Presented for CRC
Data from the KRYSTAL-1 trial show promise of adagrasib as monotherapy and in combination with other standard agents for colorectal cancer.
Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel
Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.
Frontline Regorafenib Plus Pembrolizumab Reveals Antitumor Activity in HCC
Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.
Lenvatinib-Pembrolizumab Combo Improves Outcomes in Certain Patients With Advanced Melanoma
In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma efficacy results continue to show a durable response.
Clinically Significant Improvement Observed With D-0316 for Subset of Patients with T790M+ and EGFR+ NSCLC
Patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior treatment experienced a clinically meaningful efficacy when treated with D-0316.
2 Clarke Drive Cranbury, NJ 08512